Pharmaceuticals

ACE Inhibitors Industry Overview 2025: Growth Projections and Market Trends

November 11, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The ACE Inhibitors Market Size During 2025–2029?

The ACE inhibitors market has consistently expanded in size over recent years. It is anticipated to expand from $7.15 billion in 2024 to $7.41 billion in 2025, with a compound annual growth rate (CAGR) of 3.6%. The market’s past growth has been driven by factors including risen cardiovascular disease incidence, an increased aging population, the clinical effectiveness and safety profile of these inhibitors, the prevalence of diabetes, and regulatory endorsement and guidelines.

The ACE inhibitors market size is anticipated to show robust growth over the next few years. It is projected to expand to $9.42 billion in 2029, progressing at a compound annual growth rate (CAGR) of 6.2%. This expected growth during the forecast period can be attributed to the increasing global burden of cardiovascular diseases, the broadening of hypertension treatment guidelines, advancements in combination therapies, a concentrated effort on heart failure management, and enhanced awareness and access to healthcare. Significant trends for the forecast period include a strong emphasis on kidney protection, a preference for renin-angiotensin system inhibitors, generic competition alongside pricing pressures, the implementation of patient-centric approaches in healthcare, and various regulatory updates and safety considerations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

Which Drivers Are Supporting Growth Of The ACE Inhibitors Market?

The rising occurrence of hypertension disorders is projected to fuel the expansion of the ACE inhibitors market. High blood pressure, medically termed hypertension, is a condition marked by increased pressure within blood vessels. ACE inhibitors, or angiotensin-converting enzyme inhibitors, are a class of medications used to manage and treat hypertension. These drugs function by relaxing blood vessels, thereby reducing blood pressure and improving blood flow. As an illustration, in March 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported that approximately 1.28 billion adults between the ages of 30 and 79 globally were affected by hypertension, with a majority (two-thirds) residing in low- and middle-income nations. Over the last 30 years, the count of people aged 30-79 with hypertension has risen by 650 million. Moreover, an estimated 46% of adults suffering from hypertension are unaware of their ailment due to a lack of diagnosis. Consequently, the growing prevalence of hypertension disorders is propelling the growth of the ACE inhibitors market.

How Is The ACE Inhibitors Market Segmented?

The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

Which Competitive Trends Are Defining The ACE Inhibitors Market Structure?

Product innovation represents a prominent and expanding trend within the ACE inhibitors market. Major companies operating in the ACE inhibitors market are actively concentrating on developing novel products to fortify their standing and secure a competitive edge. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, announced the FDA’s endorsement of FILSPARI (sparsentan), a groundbreaking non-immunosuppressive therapy designed for patients suffering from IgA nephropathy (IgAN). Treatments for such conditions often include systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, such as angiotensin-receptor blockers (ARBs). FILSPARI is distinguished as the sole approved non-immunosuppressive therapy, offered as a once-daily oral medicine, specifically engineered to treat adults with primary IgAN who are at risk of rapid disease progression and typically exhibit a UPCR of less than 1.5 g/g and proteinuria.

Who Are The Key Multinational Companies Dominating The ACE Inhibitors Market?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

How Do Regional Market Performances Compare Within The ACE Inhibitors Industry?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The ACE Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

Browse Through More Reports Similar to the Global ACE Inhibitors Market 2025, By The Business Research Company

Synthetic Biology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/synthetic-biology-global-market-report

Digestive Enzyme Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digestive-enzyme-global-market-report

Specialty Enzyme Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/specialty-enzyme-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795